TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Adial Pharmaceuticals ( (ADIL) ) just unveiled an update.
On November 25, 2025, Adial Pharmaceuticals entered into a warrant inducement agreement with an institutional investor, leading to the exercise of existing warrants for approximately $2.86 million in gross proceeds. The deal, which closed on November 28, 2025, involves issuing new unregistered Series F Warrants and is expected to support the company’s working capital and general corporate purposes.
The most recent analyst rating on (ADIL) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Adial Pharmaceuticals stock, see the ADIL Stock Forecast page.
Spark’s Take on ADIL Stock
According to Spark, TipRanks’ AI Analyst, ADIL is a Underperform.
Adial Pharmaceuticals’ overall stock score is low due to ongoing financial struggles, including a lack of revenue and reliance on external funding. Technical analysis provides no strong directional signal, and valuation metrics are weak due to negative earnings. However, the recent FDA approval for AD04 offers a positive strategic outlook, but this is not enough to counteract the financial and operational challenges currently faced.
To see Spark’s full report on ADIL stock, click here.
More about Adial Pharmaceuticals
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders. The company’s lead investigational drug, AD04, targets Alcohol Use Disorder and has shown promising results in clinical trials.
Average Trading Volume: 596,934
Technical Sentiment Signal: Sell
Current Market Cap: $7.52M
For a thorough assessment of ADIL stock, go to TipRanks’ Stock Analysis page.